Form 4: Elutia CFO Matthew Ferguson Reports Stock Transactions Following RSU Vesting

Elutia Inc.'s CFO, Matthew Ferguson, reports the acquisition and disposal of Class A Common Stock related to the vesting of restricted stock units (RSUs) following FDA clearance of EluPro.

Summary

• On August 12, 2024, Matthew Ferguson, CFO of Elutia Inc., reported transactions involving the company's Class A Common Stock.
• These transactions are related to the vesting of 50,000 restricted stock units (RSUs) granted on January 31, 2024.
• The vesting was contingent upon FDA clearance of the company's CanGarooRM antibiotic-eluting biologic envelope, now known as EluPro, which occurred on June 14, 2024.
• The RSUs vested on August 12, 2024, the first business day of the next open trading window after the FDA clearance.
• Ferguson acquired 50,000 shares of Class A Common Stock upon vesting of the RSUs.
• 17,840 shares were withheld by the issuer to satisfy tax withholding requirements at a price of $2.84 per share.
• Following these transactions, Ferguson beneficially owns 289,983 shares of Class A Common Stock directly.

Sentiment

Score: 7

Explanation: The sentiment is neutral to slightly positive. The vesting of RSUs indicates the achievement of a key milestone (FDA clearance), which is generally positive. The CFO's continued ownership suggests confidence. However, the document is primarily a regulatory filing and doesn't offer strong positive or negative signals.

Positives

• The vesting of RSUs indicates that a milestone (FDA clearance of EluPro) was achieved.
• The CFO's continued direct ownership of 289,983 shares suggests confidence in the company.

Future Outlook

The document does not contain specific forward-looking statements beyond the vesting conditions of the RSUs.

Industry Context

This filing reflects standard executive compensation practices in the biotechnology industry, where RSUs are commonly used to incentivize performance and align management interests with those of shareholders. FDA clearance is a critical milestone for companies like Elutia, often triggering vesting events.

Comparison to Industry Standards

• RSU grants are a common form of executive compensation in the biotech industry, similar to companies like Medtronic or Boston Scientific.
• The vesting of RSUs upon FDA approval is a standard practice to incentivize the achievement of regulatory milestones.
• Tax withholding on RSU vesting is a universal practice across publicly traded companies.

Stakeholder Impact

• Shareholders may view the FDA clearance and subsequent RSU vesting as a positive sign of company progress.
• Employees may be motivated by the achievement of the milestone and the associated executive compensation.

Key Dates